Aigen Investment Management LP Takes $74,000 Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

Aigen Investment Management LP purchased a new stake in Verve Therapeutics, Inc. (NASDAQ:VERV) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 15,231 shares of the company’s stock, valued at approximately $74,000.

A number of other hedge funds have also added to or reduced their stakes in the company. Los Angeles Capital Management LLC increased its stake in Verve Therapeutics by 8.2% in the third quarter. Los Angeles Capital Management LLC now owns 262,393 shares of the company’s stock valued at $1,270,000 after acquiring an additional 19,925 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Verve Therapeutics by 78.7% in the third quarter. Harbor Capital Advisors Inc. now owns 53,524 shares of the company’s stock valued at $259,000 after acquiring an additional 23,565 shares during the last quarter. US Bancorp DE increased its stake in Verve Therapeutics by 1,631.7% in the third quarter. US Bancorp DE now owns 18,806 shares of the company’s stock valued at $91,000 after acquiring an additional 17,720 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Verve Therapeutics by 65.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,276 shares of the company’s stock valued at $79,000 after acquiring an additional 6,412 shares during the last quarter. Finally, PFG Investments LLC bought a new position in Verve Therapeutics in the third quarter valued at approximately $53,000. 97.11% of the stock is owned by institutional investors.

Analyst Ratings Changes

VERV has been the topic of a number of research reports. Canaccord Genuity Group boosted their target price on shares of Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Royal Bank of Canada decreased their target price on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, HC Wainwright decreased their target price on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th.

Verve Therapeutics Stock Performance

Shares of NASDAQ:VERV opened at $4.79 on Monday. The firm has a market cap of $405.52 million, a PE ratio of -1.95 and a beta of 1.75. The firm’s fifty day moving average is $5.45 and its 200-day moving average is $5.67. Verve Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $19.34.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.11. The company had revenue of $6.87 million for the quarter, compared to analyst estimates of $2.75 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. Verve Therapeutics’s revenue was up 120.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.72) earnings per share. Sell-side analysts forecast that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.